Ulcerative colitis (UC) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051140
Expand allThis document outlines details of PBS-subsidised biological medicines for patients with moderate to severe ulcerative colitis (UC).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
On this page:
Ulcerative colitis (UC) adult quick reference
Ulcerative colitis (UC) paediatric quick reference
Ulcerative colitis (UC) adult quick reference
Table 1
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial PB127 form |
Written Electronic S85: adalimumab etrasimod* golimumab infliximab s.c. ozanimod tofacitinib upadacitinib ustekinumab s.c. vedolizumab s.c. S100: infliximab i.v. ustekinumab i.v. vedolizumab i.v. |
No |
OPA |
Must be treated by a:
|
Yes - immediate or delayed assessment (delayed if free text field used) |
|
Grandfather PB376 form |
Written Electronic S85: etrasimod* |
No |
OPA |
Must be treated by a:
|
Yes |
|
Dose modification |
Telephone Electronic S85: upadacitinib |
No |
OPA |
Must be treated by a:
|
Yes |
|
Dose escalation (initial/re-initiation) |
Streamlined S85: ozanimod |
No |
N/A |
Must be treated by a:
|
N/A |
|
Continuing - originator brands |
Telephone Electronic S85: adalimumab etrasimod* golimumab infliximab s.c. ozanimod tofacitinib upadacitinib ustekinumab s.c. vedolizumab s.c. S100: infliximab i.v. vedolizumab i.v. |
No |
OPA |
Must be treated by a:
|
Yes |
|
Subsequent continuing - biosimilar brands |
Streamlined S85: adalimumab S100: infliximab i.v. (Telephone for increased quantities of infliximab i.v. for patients >100kg) |
No |
N/A |
Must be treated by a:
|
N/A |
|
Change or Recommencement after a break (<5 years) PB245 form |
Written Electronic S85: Adalimumab etrasimod* golimumab infliximab s.c. ozanimod tofacitinib upadacitinib ustekinumab s.c. vedolizumab s.c. S100: infliximab i.v. ustekinumab i.v. vedolizumab i.v. |
No |
OPA |
Must be treated by a:
|
Yes -immediate or delayed assessment (delayed if free text field used) |
|
Recommencement after a break (>5 years) PB245 form |
Written Electronic S85: Adalimumab etrasimod* golimumab infliximab s.c. ozanimod tofacitinib upadacitinib ustekinumab s.c. vedolizumab s.c. S100: infliximab i.v. ustekinumab i.v. vedolizumab i.v. |
No |
OPA |
Must be treated by a:
|
Yes |
|
Balance of supply |
Telephone Electronic S85: adalimumab etrasimod* golimumab infliximab s.c. ozanimod tofacitinib upadacitinib ustekinumab s.c. vedolizumab s.c. S100: infliximab i.v. vedolizumab i.v |
No |
OPA |
Must be treated by a:
|
Yes |
Note: Patients under 18 can apply for etrasimod treatment using restrictions/application forms for adult patients. See: Treatment specifics and FAQs from Service Officers for more details.
Ulcerative colitis (UC) paediatric quick reference
Table 2
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial PB215 form |
Written Electronic S85: adalimumab S100: infliximab i.v. |
No |
OPA |
Must be treated by a:
|
Yes -delayed assessment (delayed if free text field used) |
|
Continuing - originator brands |
Telephone Electronic S85: adalimumab S100: infliximab i.v. |
No |
PA |
Must be treated by a:
|
Yes |
|
Continuing - biosimilar brands |
Streamlined S85: adalimumab S100: infliximab i.v. (Telephone for increased quantities of infliximab i.v. for patients >100kg) |
No |
N/A |
Must be treated by a:
|
N/A |
|
Change or Recommencement after a break (<5 years) PB246 form |
Written Electronic S85: adalimumab S100: infliximab i.v |
No |
OPA |
Must be treated by a:
|
Yes - immediate or delayed assessment (delayed if free text field used) |
|
Recommencement after a break (>5 years) PB246 form |
Written Electronic S85: Adalimumab S100: infliximab i.v. |
No |
OPA |
Must be treated by a:
|
Yes |
|
Balance of supply |
Telephone Electronic S85: adalimumab S100: infliximab i.v |
No |
OPA |
Must be treated by a:
|
Yes |
Delayed assessment
Delayed assessment due to:
- contraindication and/or intolerance to prior therapies
- drug name(s) of prior therapies
Table 3: this table lists the details of what to check for the delayed assessment and common acronyms.
Common acronyms
- LFT - Liver function tests
- GI toxicity - Gastrointestinal
- N+V - Nausea and vomiting
Escalate to a Pharmaceutical Adviser (PA) by phone if unsure of the acronym and/or drug name used.